Drug Trial Radar · NCT04793139
Efficacy and Safety of Camrelizumab in Real-World Prospective Study
Last checked: Nov 20, 2026Latest source record: Mar 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Apr 1, 2021
Primary completion
Jun 30, 2024
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Guangdong Association of Clinical TrialsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 11, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This observational real-world study is designed to evaluate the efficacy and safety of camrelizumab for the treatment of Chinese NSCLC patients.
Conditions
- Non-small Cell Lung Cancer
Interventions
CamrelizumabDrug
Camrelizumab-treated advanced NSCLC Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AE,Grade 3-5Time frame: From April 1, 2021 to Septeember 30, 2024
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.